Specialized Research

Thymosin Alpha-1

Also known as: Tα1, Zadaxin, Timosina Alfa-1

Molecular Identifiers

Molecular Formula

C129H215N33O55

CAS Number

62304-98-7

PubChem CID

16130571

Molecular Weight

3108 Da

Overview

Immunomodulatory peptide of 28 amino acids originally isolated from the thymus. Activates dendritic cells, promotes T lymphocyte maturation and enhances the adaptive immune response. Approved in several countries for hepatitis B and C.

Sequence (1 letter): SDAAVDTSSEITTKDLKEKKEVVEEAEN
Extended notation: Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Half-life

~2 hours

Administration Route

Subcutaneous

Category

Specialized Research

Mechanism of Action

  • Dendritic cell activation and antigen presentation
  • Promotion of T lymphocyte maturation and differentiation
  • Increased NK (natural killer) cell activity
  • Cytokine modulation (IL-2, IFN-α, IFN-γ)
  • Enhancement of vaccine response

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 1.6 mg per injection
Frequency Twice per week
Timing Any time of day
Duration 6-12 months (hepatitis) or 2-4 week cycles (immunomodulation)

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Erythema
  • Mild fatigue
  • Low-grade fever (rare)

Product Properties

Purity >99%
Appearance White lyophilized powder
Source Solid-phase peptide synthesis (SPPS)

Presentations & Preparation

Vials of Thymosin Alpha-1 found in the research market:

1.6 mg3 mg10 mg

Reconstitution

  • Diluent: Bacteriostatic water or water for injection
  • Volume: 1 ml per 1.6 mg vial
  • Slowly inject diluent
  • Gently swirl without shaking
  • Use immediately after reconstitution

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (use within 24 hours)
  • Do not freeze
  • Protect from light
Reconstitution Calculator

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily